Disrupting GPCR complexes with smart drug-like peptides

Gallo, María, 1989-; Defaus, Sira; Andreu Martínez, David

doi:http://dx.doi.org/10.3390/pharmaceutics14010161

Disrupting GPCR complexes with smart drug-like peptides

License

Citation

Gallo M, Defaus S, Andreu D. Disrupting GPCR complexes with smart drug-like peptides. Pharmaceutics. 2022;14(1):161. DOI: 10.3390/pharmaceutics14010161

Abstract

G protein-coupled receptors (GPCRs) are a superfamily of proteins classically described as monomeric transmembrane (TM) receptors. However, increasing evidence indicates that many GPCRs form higher-order assemblies made up of monomers pertaining to identical (homo) or to various (hetero) receptors. The formation and structure of these oligomers, their physiological role and possible therapeutic applications raise a variety of issues that are currently being actively explored. In this context, synthetic peptides derived from TM domains stand out as powerful tools that can be predictably targeted to disrupt GPCR oligomers, especially at the interface level, eventually impairing their action. However, despite such potential, TM-derived, GPCR-disrupting peptides often suffer from inadequate pharmacokinetic properties, such as low bioavailability, a short half-life or rapid clearance, which put into question their therapeutic relevance and promise. In this review, we provide a comprehensive overview of GPCR complexes, with an emphasis on current studies using GPCR-disrupting peptides mimicking TM domains involved in multimerization, and we also highlight recent strategies used to achieve drug-like versions of such TM peptide candidates for therapeutic application.